For its fourth fiscal quarter (ending December 31), iRadimed Corp (NASDAQ: IRMD) has reported a 14% increase in E.P.S. from $0.36 a year ago to $0.41 in the current quarter. However, this result fell short of the consensus estimate of $0.44 by $-0.03. For the latest four quarters through December 31, E.P.S. were $1.52 compared to $1.36 a year ago — an increase of 12%.
Recent Price Action
On 2/13/25, iRadimed Corp (NASDAQ: IRMD) stock suffered a large decline of -8.4%, closing at $55.40. Moreover, this decline was accompanied by exceptionally high trading volume at 241% of normal. The stock has declined -11.6% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
iRadimed has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. iRadimed has a very low Appreciation Score of 12 but a very high Power Rating of 86, with the Low Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment